Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?

CONCLUSION: There is currently only indirect preclinical evidence to support a rationale for dual therapy with anti-calcitonin gene-related peptide monoclonal antibodies and botulinum toxin type A for chronic migraine prevention. Rigorous studies evaluating clinical efficacy, safety, and cost-effectiveness are needed. PMID: 32437038 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32437038?dopt=Abstract

Source: Headache - May 20, 2020 Category: Neurology Authors: Pellesi L, Do TP, Ashina H, Ashina M, Burstein R Tags: Headache Source Type: research